These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 645512

  • 21. Use of prostaglandin E1 for maintaining the patency of the ductus arteriosus.
    Noah ML.
    Adv Prostaglandin Thromboxane Res; 1978; 4():355-62. PubMed ID: 347914
    [Abstract] [Full Text] [Related]

  • 22. Blockers of prostaglandin synthesis: a novel therapy in the management of the premature human infant with patent ductus arteriosus.
    Friedman WF, Printz MP, Kirkpatrick SE.
    Adv Prostaglandin Thromboxane Res; 1978; 4():373-81. PubMed ID: 565580
    [No Abstract] [Full Text] [Related]

  • 23. Ductus arteriosus dilatation by prostaglandin E1 in infants with pulmonary atresia.
    Heymann MA, Rudolph AM.
    Pediatrics; 1977 Mar; 59(3):325-9. PubMed ID: 840551
    [Abstract] [Full Text] [Related]

  • 24. Proceedings: Emergency treatment of certain cyanotic heart defects with prostaglandin E2.
    Olley PM, Coceani F.
    Br Heart J; 1976 Aug; 38(8):877. PubMed ID: 973917
    [No Abstract] [Full Text] [Related]

  • 25. Prostaglandin and damage to ductus arteriosus.
    Moulaert AJ, Gittenberger AC, Harinck E.
    Lancet; 1977 Mar 26; 1(8013):703-4. PubMed ID: 66503
    [No Abstract] [Full Text] [Related]

  • 26. Ductus arteriosus: developmental response to endogenous prostaglandins, oxygen, and indomethacin.
    Clyman RI.
    Adv Prostaglandin Thromboxane Res; 1980 Mar 26; 7():887-90. PubMed ID: 6989208
    [No Abstract] [Full Text] [Related]

  • 27. Letter: Medical manipulation of the ductus arteriosus.
    Christensen NC, Fabricus J.
    Lancet; 1975 Aug 30; 2(7931):406-7. PubMed ID: 51207
    [No Abstract] [Full Text] [Related]

  • 28. Pharmacological manipulation of the ductus arteriosus.
    Silove ED.
    Arch Dis Child; 1986 Sep 30; 61(9):827-9. PubMed ID: 3767410
    [No Abstract] [Full Text] [Related]

  • 29. [Prostaglandin treatment of ductus-dependent congenital heart defects].
    Olsson B, Björkhem G, Lundström NR.
    Lakartidningen; 1984 Oct 03; 81(40):3619-22. PubMed ID: 6541738
    [No Abstract] [Full Text] [Related]

  • 30. Prostaglandins and the ductus arteriosus.
    Olley PM, Coceani F.
    Annu Rev Med; 1981 Oct 03; 32():375-85. PubMed ID: 7013675
    [Abstract] [Full Text] [Related]

  • 31. Effects of inhibition of prostaglandin synthesis on fetal development, oxygenation, and the fetal circulation.
    Levin DL.
    Semin Perinatol; 1980 Jan 03; 4(1):35-44. PubMed ID: 6992279
    [No Abstract] [Full Text] [Related]

  • 32. Pharmacologic use of prostaglandin E1 in infant with congenital heart disease.
    Heymann MA.
    Am Heart J; 1981 Jun 03; 101(6):837-43. PubMed ID: 7234660
    [No Abstract] [Full Text] [Related]

  • 33. [Treatment of ductus-dependent congenital heart diseases with prostaglandin E1].
    Lillquist K.
    Ugeskr Laeger; 1979 Jul 09; 141(28):1915-6. PubMed ID: 473414
    [No Abstract] [Full Text] [Related]

  • 34. Considerations on the role of prostaglandins in the ductus arteriosus.
    Coceani F, Olley PM.
    Adv Prostaglandin Thromboxane Res; 1980 Jul 09; 7():871-8. PubMed ID: 7369050
    [No Abstract] [Full Text] [Related]

  • 35. Prostaglandins and the ductus arteriosus.
    Friedman WF, Printz MP, Skidgel RA, Benson LN, Zednikova M.
    Adv Prostaglandin Thromboxane Leukot Res; 1982 Jul 09; 10():277-302. PubMed ID: 6216785
    [No Abstract] [Full Text] [Related]

  • 36. Role of circulating prostaglandin E2 in regulation of the ductus arteriosus.
    Clyman RI, Heymann MA, Mauray F.
    Adv Prostaglandin Thromboxane Leukot Res; 1983 Jul 09; 12():495-8. PubMed ID: 6221637
    [No Abstract] [Full Text] [Related]

  • 37. [Prolonged prostaglandin E-1 therapy of newborn infants with congenital heart defects].
    Kertész E, Hencz P, Tekulics P, Beviz J, Száva J, Matkó I, Kovács G.
    Orv Hetil; 1980 May 18; 121(20):1197-9. PubMed ID: 7413203
    [No Abstract] [Full Text] [Related]

  • 38. Morphologic features of the ductus arteriosus after prostaglandin E1 administration for ductus-dependent congenital heart defects.
    Park IS, Nihill MR, Titus JL.
    J Am Coll Cardiol; 1983 Feb 18; 1(2 Pt 1):471-5. PubMed ID: 6681824
    [No Abstract] [Full Text] [Related]

  • 39. Prostaglandin biosynthetic pathways in fetal lamb ductus arteriosus and lung: relationship to ductal patency and closure.
    Printz MP, Friedman WF, Skidgel RA.
    Adv Prostaglandin Thromboxane Leukot Res; 1983 Feb 18; 12():483-9. PubMed ID: 6221635
    [No Abstract] [Full Text] [Related]

  • 40. E-type prostaglandins: a new emergency therapy for certain cyanotic congenital heart malformations.
    Olley PM, Coceani F, Bodach E.
    Circulation; 1976 Apr 18; 53(4):728-31. PubMed ID: 56243
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.